Inspire Initiates Second Phase 3 Cystic Fibrosis Trial
February 13, 2008
Inspire Pharmaceuticals, Inc. announced today the initiation of TIGER-2, its second pivotal Phase 3 clinical trial with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis (CF).
TIGER-2 is beginning with enrollment in U.S. and Canadian sites, to be followed by enrollment in international sites as the trial proceeds.
Read the full press release.
| 
